ACIU AC Immune SA
Price Chart
Executive Summary
AC Immune announced an amendment to its collaboration agreement with Eli Lilly to continue developing Tau-targeting small molecules for Alzheimer's and other neurodegenerative diseases. The deal includes a CHF10 million upfront payment and potential future milestones exceeding CHF1.7 billion, with IND-enabling studies expected to begin in H1 2026.
Key Financial Metrics
Actionable Insight
The upfront payment provides non-dilutive funding to advance AC Immune's pipeline, while the massive milestone potential signals high optionality. Traders should monitor progress toward IND-enabling studies in H1 2026 as the next catalyst.
Key Facts
- Amendment extends AC Immune's collaboration with Eli Lilly on Tau Morphomer® small molecules for Alzheimer’s and other neurodegenerative diseases.
- AC Immune will receive CHF10 million upfront and is eligible for over CHF1.7 billion in future milestones plus tiered royalties in the low double digits.
- IND-enabling studies are expected to commence in H1 2026.
- Morphomer candidates are designed for oral dosing and brain penetration, with preclinical data supporting clinical relevance in inhibiting Tau aggregation.
Financial Impact
CHF10 million upfront payment and potential future payments exceeding CHF1.7 billion, plus low double-digit royalties
Risk Factors
- Future milestone payments are contingent on clinical, regulatory, and commercial success, which are highly uncertain.
- Preclinical data may not translate into clinical efficacy, particularly in complex neurodegenerative diseases.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
18d ago
|
Press Release
| $2.83 $2.46 | ▼ −13.07% | ▼ −14.73% | $2.19 (−22.61%) |
|
May 15, 2026
25d ago
|
6-K
| $2.79 $2.83 | ▲ +1.43% | ▲ +0.47% | $2.19 (−21.51%) |
|
May 12, 2026
28d ago
|
6-K
| $2.77 $2.77 | · 0.00% | ▼ −0.08% | $2.19 (−20.94%) |
|
Apr 30, 2026
5w ago
|
6-K
| $3.03 $2.92 | ▼ −3.63% | ▼ −5.36% | $2.19 (−27.72%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $3.03 $2.92 | ▼ −3.63% | ▼ −5.36% | $2.19 (−27.72%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $3.03 $2.92 | ▼ −3.63% | ▼ −5.36% | $2.19 (−27.72%) |
|
Apr 7, 2026
9w ago
|
6-K
| $3.11 $3.19 | ▲ +2.57% | ▼ −2.76% | $2.19 (−29.58%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $3.11 $3.19 | ▲ +2.57% | ▼ −2.76% | $2.19 (−29.58%) |
|
Apr 1, 2026
9w ago
|
3
| $2.76 $3.28 | ▲ +18.84% | ▲ +15.22% | $2.19 (−20.65%) |
|
Mar 13, 2026
12w ago
|
Press Release
| $3.02 $2.85 | ▼ −5.47% | ▼ −3.35% | $2.19 (−27.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access